Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating epcoritamab in combination with standard platinum-based chemotherapy and autologous hematopoietic cell transplant…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy [Phase 2]
A Phase 2 clinical trial evaluating odronextamab for relapsed or refractory diffuse large B-cell lymphoma before and after CAR T-cell therap…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma [Phase 3]
A Phase 3 open-label randomized trial comparing Rituximab plus Lenalidomide versus Rituximab plus chemotherapy followed by Rituximab in prev…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL). [Phase 2]
Phase 2, multicenter, open-label trial evaluating subcutaneous mosunetuzumab in previously untreated low tumor burden follicular lymphoma.
-
CLINICAL_TRIALS other · 2025-09-24Clinical Trial Update: Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating mosunetuzumab and polatuzumab vedotin for relapsed or refractory grade 1-3a follicular lymphoma is current…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
This clinical trial update reports that recruitment is ongoing for a study evaluating zanubrutinib in patients with Waldenström's macroglobu…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of TQB2825 injection versus immunotherapy in recurrent or refractory follicular ly…
-
EMA approval · 2025-09-19EMA Authorised: Ordspono (odronextamab) — Regeneron Ireland Designated Activity Company (DAC)
The European Medicines Agency has authorised Ordspono (odronextamab) from Regeneron Ireland DAC for follicular lymphoma with conditional app…
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]
This clinical trial update reports an early-phase study of a novel Bispecific AbTCR (anti-CD19/CD22) T-cell therapy for relapsed or refracto…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]
Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refrac…
-
CLINICAL_TRIALS other · 2025-09-08Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) [Phase 1, Phase 2]
This clinical trial update indicates that Nemtabrutinib (MK-1026) is being studied for relapsed or refractory hematologic malignancies in a …
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS research · 2025-09-03Clinical Trial Update: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma [Phase 3]
It reports an ongoing Phase 3 trial comparing shortened versus standard chemotherapy combined with immunotherapy as initial treatment for hi…
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) [Phase 1]
A Phase 1 study evaluating the safety and preliminary efficacy of INCB050465 in combination with bendamustine and obinutuzumab in relapsed o…
-
CLINICAL_TRIALS trial_result · 2025-08-20Clinical Trial Update: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. [Phase 2]
Phase 2 clinical trial evaluating Golcadomide (CELMoD) with rituximab, with or without nivolumab, for newly diagnosed follicular lymphoma; t…
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma [Phase 1]
An early-phase study at Memorial Sloan Kettering Cancer Center is evaluating measurements of cell-free DNA (cfDNA) in people with follicular…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma [NA]
A clinical trial update describes a fixed-duration regimen of zanubrutinib, bendamustine, and obinutuzumab (ZBG) as first-line therapy for t…